Amgen Inc. Stock (US0311621009): Jury patent verdict and valuation debate put shares in focus

Amgen shares trade around $355 as a U.S. jury finds the company liable in a $20 million antibody patent case, while fresh valuation work and ownership data keep the Nasdaq-listed stock on the radar of U.S. retail investors.

By AD HOC NEWS - Companies & Analysis Desk Team | June 15, 2026

Amgen Inc. stock is in focus at the start of the new week after a U.S. jury found the biotech group liable for willful infringement in an antibody patent case brought by Harbour BioMed, awarding damages of about $20.2 million, while the shares continue to trade near the mid-$350s on the Nasdaq. A separate discounted cash flow review published by GuruFocus on June 15, 2026 pegs Amgen's earnings-based intrinsic value at roughly $292 per share versus a current price around $355, flagging the stock as slightly to modestly overvalued depending on the model used. At the same time, recent ownership filings and market data show Amgen maintaining a market capitalization above $190 billion, with a dividend yield near 2.8 percent and a forward earnings profile that still attracts institutional investors.

Jury verdict in Harbour BioMed patent case adds legal overhang

The immediate legal trigger for Amgen's news flow is a U.S. patent infringement case that Harbour BioMed describes as a "landmark victory" in the antibody patent space. According to Harbour BioMed, a federal jury in the United States deliberated for roughly three hours following a trial that began on June 8, 2026, and then returned a unanimous verdict in favor of Harbour on all counts related to the so-called Grosveld patent. The company states that the jury concluded Amgen infringed the Grosveld patent, that the infringement was willful, that the patent is valid, and that Harbour BioMed is entitled to $20,203,704 in damages, the full amount requested at trial.

A separate summary from industry outlet Contract Pharma confirms that a U.S. jury found Amgen liable for patent infringement against Harbour BioMed and highlights the roughly $20 million verdict. The Hong Kong exchange filing by HBM Holdings, Harbour BioMed's parent, provides additional procedural detail, noting that the jury trial commenced on June 8, 2026 and that the verdict covered multiple liability and validity questions related to the Grosveld patent. While the award is not material relative to Amgen's overall market capitalization, the willfulness finding could influence any subsequent discussions about enhanced damages or settlement terms, and it adds another legal vector to monitor alongside the group's broader intellectual property strategy.

From a retail investor perspective, the verdict raises questions on two fronts: potential financial impact beyond the initial $20.2 million and possible implications for competitive positioning in the relevant antibody technology area. Harbour BioMed characterizes the outcome as reshaping the global antibody patent landscape, suggesting the patent at issue could touch platforms and programs beyond a single product, although detailed product-level financial ties are not disclosed in the public statements. For Amgen, the case underscores the ongoing patent and licensing risks that are inherent in biologics and antibody development, where overlapping claims and foundational research rights regularly end up tested in court.

Valuation spotlight: DCF models vs. current Amgen share price

Alongside the legal update, valuation analysis places Amgen's current price in the spotlight for U.S. investors focused on fundamentals and cash flow. GuruFocus published a discounted cash flow review on June 15, 2026 that examines Amgen's share performance and intrinsic value under several models. According to that report, Amgen's stock price has climbed about 23.1 percent over the past year, with gains of 1.6 percent over the past week and 6.4 percent over the past month going into the latest valuation snapshot. The analysis uses a current market price of approximately $355.20 per share, which is broadly in line with recent quote data from trading platform Robinhood that puts the stock at $355.22 and a market capitalization near $191.7 billion.

On an earnings-based discounted cash flow basis, GuruFocus calculates an intrinsic value of about $292.40 per share for Amgen, implying a negative margin of safety of roughly 21.5 percent relative to the $355.20 trading level. A separate free cash flow DCF model delivers an even lower intrinsic value estimate of approximately $183.01 per share, leading the service to describe the stock as modestly overvalued based on cash flows, with a large negative margin of safety. When the DCF results are combined with the platform's proprietary GF Value indicator, the consensus characterization is that Amgen appears fairly valued by the earnings model but slightly to modestly overvalued by free cash flow and GF Value metrics, prompting a cautionary stance on valuation.

Those high-level valuation numbers sit alongside more conventional metrics that many U.S. retail investors track day to day. Real-time quote data from Robinhood lists Amgen at $355.22 per share with a price-to-earnings ratio of about 24.7, a trailing dividend yield of roughly 2.8 percent and a daily trading range between $351.96 and $358.17 for the last completed session. The same data show the stock trading less than 1 percent above its intraday low and under 1 percent below its intraday high, indicating relatively contained volatility in the latest session despite the legal headlines and valuation debate. These numbers suggest that while fundamental models may flag limited margin of safety, the market has so far kept Amgen trading in a relatively tight band near its recent highs.

Ownership flows and analyst context for Amgen shares

Fresh ownership filings also point to ongoing institutional interest in Amgen despite the legal and valuation headlines. MarketBeat reports that Resources Management Corp CT ADV acquired a new position in Amgen during a recent quarter, according to a Form 13F filing, adding the biotech giant to its managed portfolios. That filing underscores that Amgen remains a core large-cap holding for a range of asset managers seeking exposure to established biopharmaceutical cash flows, even as patent risk and pricing pressure remain part of the investment narrative. MarketBeat further summarizes that Amgen has issued guidance for fiscal year 2026 in the range of $21.70 to $23.10 in earnings per share, and that Wall Street research analysts as a group expect the company to post about $22.38 in EPS for the current year. Those figures help frame the earnings outlook that underpins both dividend sustainability and DCF-based valuation models.

On the sentiment side, MarketBeat notes that Amgen carries an average analyst rating of "Hold" with a consensus price target around $354.12. That target is essentially in line with the current trading level around the mid-$350s, signaling that, on average, covering analysts do not see significant upside or downside from recent prices based on their published models. Separate commentary referenced by trading platform Robinhood highlights that Morgan Stanley recently raised its price target on Amgen to $340 from $332 while maintaining an Equal Weight rating, reinforcing the perception that the stock is fairly valued to slightly rich relative to large-cap biotech peers. Taken together, the hold-leaning analyst stance, incremental institutional buying and cautious DCF conclusions all feed into a picture of a mature, cash-generating pharma name where expectations are balanced between pipeline opportunity and lingering patent and pricing challenges.

Beyond the courtroom and valuation spreadsheets, Amgen's operating story in 2026 continues to revolve around its pipeline, new product launches and lifecycle management of established therapies. Specialist law and industry sources note that Amgen recently provided an update on its phase 3 clinical trial for ABP 938, an 8 mg biosimilar candidate to Regeneron and Bayer's Eylea HD, indicating that the company remains active in the high-value ophthalmology biosimilar space. In oncology, Amgen is also advancing and commercializing therapies such as tarlatamab-dlle (Imdelltra), which has received accelerated approval in the United States for adult patients with extensive-stage small cell lung cancer that has progressed following platinum-based chemotherapy. The Imdelltra product information highlights both the opportunity and the risk profile typical of advanced oncology agents, listing cytokine release syndrome, neurologic events and embryo-fetal toxicity among key safety considerations, while pointing to clinical response rates that support further development and post-approval evidence generation.

These pipeline and product details matter for valuation because they inform long-term cash flow assumptions, especially as Amgen, like other big biopharma companies, navigates a wave of patent expirations and biosimilar competition on older blockbuster drugs. Management has previously emphasized that newer growth products and biosimilar launches can help offset patent pressure and position 2026 and beyond as a potential "springboard" period for renewed revenue momentum, though exact revenue contributions by product are not specified in the sources reviewed. For investors weighing the legal setback in the Harbour BioMed case against the broader portfolio, the key question is whether the combination of established franchises, biosimilar plays and first-in-class or best-in-class pipeline programs can sustain earnings in the EPS range targeted by management while supporting the current dividend and share repurchase activity.

From a sector perspective, Amgen trades as a major constituent of U.S. large-cap equity indices and benchmarks, giving it substantial weight in health care and biotechnology exchange-traded funds. The stock is listed on the Nasdaq under the ticker AMGN and is widely followed as one of the larger biopharma names in the U.S. market. Its blend of cash generative legacy products, exposure to high-growth therapeutic areas such as oncology and inflammation, and ongoing legal and pricing challenges aligns with broader themes facing the U.S. drug industry, including scrutiny of drug prices, competition from biosimilars and generics, and the importance of intellectual property in securing returns on R&D investments. The Harbour BioMed verdict, in this context, serves as a reminder that even well-established companies can face meaningful legal and patent headwinds that need to be incorporated into risk assessments.

For U.S. retail investors, the latest developments around Amgen highlight a balance of opportunity and risk rather than a one-sided story. On one hand, the stock offers exposure to a diversified biopharmaceutical portfolio, ongoing clinical programs and a dividend yield close to 3 percent combined with large-cap liquidity and broad index inclusion. On the other hand, valuation frameworks that emphasize discounted cash flows and GF Value indicators suggest that much of this narrative may already be reflected in the current price around the mid-$350s, while the Harbour BioMed decision and other legal or regulatory issues add to the list of factors that could affect future cash flows. How the market ultimately weighs these cross-currents will depend on subsequent legal steps in the patent matter, updates on Amgen's key clinical and commercial programs, and any changes to earnings guidance or capital allocation policies over the coming quarters.

Against that backdrop, Amgen's stock today looks less like an undiscovered story and more like a mature biopharma name where incremental news on legal outcomes, pipeline progress and pricing policy may tilt sentiment at the margin. For now, the combination of a willfulness finding in a U.S. patent case, fair-to-slightly-rich valuation signals from DCF and GF Value models, and a hold-leaning analyst consensus keeps Amgen firmly on the radar of U.S. investors who follow large-cap biotechnology.

Amgen fundamentals at a glance

• Name: Amgen Inc.
• Industry: Biopharmaceuticals and biotechnology
• Headquarters: Thousand Oaks, California, United States
• Core markets: United States, Europe, Asia-Pacific and other global biopharma markets
• Revenue drivers: Innovative biologic drugs, oncology and inflammation therapies, cardiovascular medicines, biosimilars and emerging pipeline products
• Listing: Nasdaq, ticker symbol AMGN
• Trading currency: US dollars (USD)

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.